Abstract
It has been suggested that it is unwise to employ neuraminidase inhibitors in order to diminish the risk of influenza-related complications in cases of infection with the new influenza A(H1N1). However, the major argument, i.e. that the beneficial effects shown in the published evidence may be due to age differences between treatment and placebo groups, can easily be refuted. The Netherlands' policy to limit treatment to those patient groups who are considered at high risk of influenza complications is a sound one. In addition, it is endorsed by recent guidelines of the WHO and CDC.
| Translated title of the contribution | Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations |
|---|---|
| Original language | Dutch |
| Pages (from-to) | B486 |
| Journal | Nederlands Tijdschrift voor Geneeskunde |
| Volume | 153 |
| Publication status | Published - 2009 |
| Externally published | Yes |
Keywords
- Age Factors
- Antiviral Agents
- Centers for Disease Control and Prevention (U.S.)
- Enzyme Inhibitors
- Humans
- Influenza A Virus, H1N1 Subtype
- Influenza, Human
- Neuraminidase
- Oseltamivir
- Practice Guidelines as Topic
- Risk Factors
- United States
- World Health Organization